Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pabinafusp Alfa (JR-141) in MPS II
NCT03359213Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pabinafusp alfa in mucopolysaccharidosis type II, sponsored by JCR Pharmaceuticals. Started Jul 2018; status: completed.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT03359213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359213.